Alector Appoints Dr. Arnon Rosenthal as CSO

Ticker: ALEC · Form: 8-K · Filed: 2025-03-28T00:00:00.000Z

Sentiment: neutral

Topics: executive-appointment, personnel, biotech

TL;DR

Alector names new CSO, Dr. Arnon Rosenthal, to drive scientific strategy.

AI Summary

Alector, Inc. announced on March 25, 2025, the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer. Dr. Rosenthal, previously a Senior Vice President of Research, will lead Alector's scientific strategy and research efforts. This appointment is part of the company's ongoing efforts to advance its pipeline of therapies for neurodegenerative diseases.

Why It Matters

The appointment of a new Chief Scientific Officer can signal a renewed focus on research and development, potentially impacting the company's future drug discovery and clinical trial progress.

Risk Assessment

Risk Level: low — This filing is an administrative update regarding an executive appointment, not a material financial event.

Key Players & Entities

FAQ

What is the effective date of Dr. Arnon Rosenthal's appointment as Chief Scientific Officer?

The filing does not explicitly state an effective date for the appointment, but it was reported on March 25, 2025.

What was Dr. Rosenthal's previous role at Alector, Inc.?

Dr. Rosenthal previously served as a Senior Vice President of Research at Alector, Inc.

What is the primary responsibility of the Chief Scientific Officer at Alector, Inc.?

The Chief Scientific Officer is responsible for leading the company's scientific strategy and research efforts.

What is Alector, Inc.'s primary business focus?

Alector, Inc. focuses on developing therapies for neurodegenerative diseases.

Under which section of the 1934 Act is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000950170-25-046756.txt : 20250328 0000950170-25-046756.hdr.sgml : 20250328 20250328160508 ACCESSION NUMBER: 0000950170-25-046756 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250325 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250328 DATE AS OF CHANGE: 20250328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 25785889 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 8-K 1 alec-20250325.htm 8-K 8-K false 0001653087 0001653087 2025-03-25 2025-03-25   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025     Alector, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-38792 82-2933343 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           131 Oyster Point Blvd. Suite 600   South San Francisco , California   94080 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 231-5660     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   ALEC   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2025, Dr. Gary Romano gave notice of his decision to resign from his position as Chief Medical Officer of Alector, Inc. (the “Company”) in order to pursue other opportunities. His resignation will be effective on April 25, 2025. Dr. Romano has served as the Company’s Chief Medical Officer since May 2022, and the Company extends its gratitude to Dr. Romano for his years of service and contributions to the Company. SIGNATURE

View on Read The Filing